Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon and Boehringer Ingelheim Enter Oncology Research Service Collaboration

Published: Tuesday, April 23, 2013
Last Updated: Tuesday, April 23, 2013
Bookmark and Share
Five year collaboration will support Boehringer Ingelheim’s drug discovery programs.

Horizon Discovery Ltd (Horizon) has announced that it has signed a research service collaboration agreement with Boehringer Ingelheim.

Horizon will support Boehringer Ingelheim’s oncology programs by using its Discovery Toolbox for research projects and profiling of compounds at the hit-to-lead, lead optimization and pre-clinical stages to elucidate their anti-cancer properties and help guide drug discovery programs.

Under the terms of the collaboration, Horizon will evaluate compounds across a broad panel of X-MAN isogenic models and selected 2D/3D phenotypic assays, and will provide an FTE and access to its custom cell line generation services to support the programs.

Horizon will also apply its proprietary genome editing technology GENESIS™ to develop human isogenic disease model cell lines, according to Boehringer Ingelheim’s specifications.

Using GENESIS, Horizon is able to alter any endogenous gene sequence of human or mammalian cell lines quickly, reliably and without unwanted and confounding genotypes and/or phenotypes. The resulting high quality cell lines accurately model the disease-causing mutations found in patients.

Kam Dhaliwal, Vice President of Sales, Horizon, said “We are delighted that Boehringer Ingelheim has selected Horizon as a partner for its drug discovery programs, in recognition of the value our X-MAN cell lines and drug discovery services can add to the search for novel treatments for cancer."

Financial terms of the agreement were not disclosed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon, Sophia Genetics Partner to Improve NGS Testing for Cancer
Partnership combines Horizon’s HDx™ Reference Standards with Sophia Genetics’ artificial intelligence.
Friday, November 18, 2016
Horizon Discovery Enters Chinese Clinical Diagnostics Market
Three leading Chinese diagnostic kit manufacturers have initiated clinical trials using Horizon HDx™ Reference Standards.
Thursday, November 17, 2016
Horizon Discovery, CareDx Signs OEM Agreement
Under the agreement, company will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for the monitoring of transplanted organ rejection.
Thursday, November 10, 2016
Horizon Discovery Announces Two Fresh Licensing Agreements
Horizon Discovery licenses biomanufacturing cell lines to Centre for Process Innovation (CPI) and National Institute for Bioprocessing Research and Training (NIBRT).
Tuesday, September 13, 2016
Horizon, Fulcrum Launch Collaboration
Horizon Discovery and Fulcrum Therapeutics form collaboration for novel CRISPR-based target discovery in genetic diseases.
Tuesday, September 06, 2016
Horizon, Ventana Sign Co-Development Agreement
The agreement covers the development, manufacture and commercialisation of cell line derivative materials for use as IHC Reference Standards.
Friday, September 02, 2016
Wistar, Horizon Ink Exclusive License Deal
The Wistar Institute has granted Horizon Discovery an exclusive license to 153 of its Melanoma Patient-Derived Xenograft models.
Thursday, July 21, 2016
Horizon, Centauri Therapeutics Launch Collaboration
Joint venture creates a differentiated new player in the rapidly growing immuno-oncology market, currently valued at £25 billion.
Thursday, March 03, 2016
Horizon Signs Three Diagnostic Agreements Worth an Initial $3.3 Million
Agreements with three global companies for test development and validation.
Thursday, November 26, 2015
Horizon Launches New E-commerce Platform and Expands UK Headquarters
Key investment includes an integrated web-shop and Enterprise Resource Planning system to support further scale and revenue growth.
Thursday, October 29, 2015
Horizon, Swift Partner on Genomic Reference Standards
Standards to be used to support validation, consistency and accuracy of the panel.
Wednesday, October 28, 2015
Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon Enters Licensing Agreement with LakePharma
The terms of the license cover commercial use of a genetically-engineered Chinese Hamster Ovary (CHO) cell line, developed by Horizon and adapted to manufacturing conditions by LakePharma.
Thursday, September 17, 2015
Horizon Enters Bioproduction Cell Line Licensing Agreement with LakePharma, Inc.
LakePharma to take a full commercial license for GS null CHO K1 cell line from Horizon for improved efficiency in biopharmaceutical manufacturing.
Wednesday, September 16, 2015
Horizon, Abcam Sign License and Supply Agreement
Horizon Discovery Group plc and Abcam plc have announced the formation of a license and supply agreement between the two companies.
Wednesday, September 09, 2015
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Transporting Microscopic Cargo Between Human Cells
Scientists have developed a virus-inspired delivery system for material transport between cells.
Metabolite Promotes Cancer Cell Transformation
Researchers have identified a metabolite that promotes cancer cell transformation and colorectal cancer spread.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Zika’s Entry Points
Discovery shows Zika infection of neural progenitor cells occurs regardless of AXL production, which was thought to be the main vector for the virus.
New Form of Autism Found
An international team of researchers have identified a new form of syndromic autism.
Radiation-Free Imaging in the Brain
Scientists create sensors that use proteins to detect particular targets through induced blood flow changes.
Failings in Conveying Risks of Undercooked Meat
A study has found that restaurants do not communicate the risks of eating undercooked meats.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!